open45noIt is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (P<0.001). Eighty-e...
In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor ...
The majority of patients with chronic myeloid leukemia are successfully managed with life-long treat...
Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for around 15...
open45noIt is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic...
It is judged safe to discontinue treatment with tyrosine kinase inhibitors for chronic myeloid leuke...
It is judged safe to discontinue treatment with tyrosine kinase inhibitors for chronic myeloid leuke...
Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic...
Background: In the last 10 years different studies analyzed the outcome of patients (pts) with sust...
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevan...
Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered f...
Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for around 15...
In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor ...
The majority of patients with chronic myeloid leukemia are successfully managed with life-long treat...
Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for around 15...
open45noIt is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic...
It is judged safe to discontinue treatment with tyrosine kinase inhibitors for chronic myeloid leuke...
It is judged safe to discontinue treatment with tyrosine kinase inhibitors for chronic myeloid leuke...
Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic...
Background: In the last 10 years different studies analyzed the outcome of patients (pts) with sust...
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevan...
Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered f...
Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for around 15...
In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor ...
The majority of patients with chronic myeloid leukemia are successfully managed with life-long treat...
Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for around 15...